ReviewCureus2025
Comprehensive Review on Association of Bipolar Disorder and Substance Abuse: Dual Diagnosis and Treatment Approaches.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pramipexole treatment and substance use disorder risk in unipolar and bipolar depression: a Swedish nationwide register study.Frontiers in psychiatry · 2026Article
- Clinical practice guidelines for the management of bipolar disorder: 2025 update.Indian journal of psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bipolar disorder (BD) and substance use disorder (SUD) usually arise in conjunction, leading to worse outcomes than when either condition exists independently. This co-occurrence is associated with a greater number of severe symptoms, longer illness duration, higher suicide rates, and increased overall health problems. The growing number of individuals affected by both BD and SUD has sparked interest in understanding their connection and finding effective treatment strategies. This research paper provides a comprehensive overview of the high rates of SUD among people with BD. It explores certain determinant factors such as genetic polymorphism, neurobiological implications, and psychosocial and environmental factors that contribute to this association. It also discusses the challenges in diagnosing both conditions, given their overlapping symptomatology, and the importance of recognizing dual diagnosis in clinical settings. Treatment options, including medications, psychotherapy, and integrated care models, are examined, focusing on tailored approaches for patients. The review also touches on the stigma surrounding dual diagnosis, which can affect treatment engagement. Lastly, it highlights the promise of innovative therapies and emphasizes the need for more research to improve detection, medical care, and attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.